Lucid Diagnostics (LUCD) EBT Growth (1y) (2021 - 2026)
Lucid Diagnostics (LUCD) EBT Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.82 Bn | 176.53 Bn | 6.27 Bn | -18.50% |
| 2 | Stryker | 129.01 Bn | 126.13 Bn | 3.81 Bn | 11.26% |
| 3 | Medtronic | 108.52 Bn | 99.30 Bn | 6.41 Bn | 45.44% |
| 4 | Boston Scientific | 68.59 Bn | 67.14 Bn | 3.61 Bn | 44.35% |
| 5 | Edwards Lifesciences | 48.35 Bn | 44.68 Bn | 1.29 Bn | 5.78% |
| 6 | Dexcom | 28.35 Bn | 27.23 Bn | 750.30 Mn | 74.66% |
| 7 | GE HealthCare Technologies | 28.11 Bn | 25.82 Bn | 1.98 Bn | -27.02% |
| 8 | Smith & Nephew | 26.89 Bn | 26.32 Bn | - | - |
| 9 | Koninklijke Philips | 24.28 Bn | 21.15 Bn | 2.07 Bn | 103.34% |
| 10 | Lucid Diagnostics | 127.57 Mn | 99.70 Mn | -325,000.00 | 48.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 48.31% |
| Dec 31, 2025 | -40.94% |
| Sep 30, 2025 | 15.96% |
| Jun 30, 2025 | 59.66% |
| Mar 31, 2025 | -153.56% |
| Dec 31, 2024 | -6.57% |
| Sep 30, 2024 | 12.93% |
| Jun 30, 2024 | 3.30% |
| Mar 31, 2024 | 34.68% |
| Dec 31, 2023 | 27.45% |
| Sep 30, 2023 | 0.98% |
| Jun 30, 2023 | 22.18% |
| Mar 31, 2023 | -32.41% |
| Dec 31, 2022 | -32.04% |
| Sep 30, 2022 | -106.25% |
| Jun 30, 2022 | -137.29% |
| Mar 31, 2022 | -235.89% |
| Dec 31, 2021 | -313.97% |
| Sep 30, 2021 | -244.12% |